Acute Coronary Syndrome (ACS) represents a significant cause of morbidity and mortality worldwide. The management of ACS is complex and requires a multifaceted approach. This article aims to provide an overview of the effective strategies for ACS management.
Risk stratification is crucial for determining the appropriate treatment strategy for ACS. The use of validated risk scores such as the GRACE or TIMI risk scores can aid in identifying high-risk patients who may benefit from early invasive strategies.
Pharmacologic therapy forms the cornerstone of ACS management. Dual antiplatelet therapy (DAPT), consisting of aspirin and a P2Y12 inhibitor, is recommended for all patients with ACS. Additionally, anticoagulants, beta-blockers, angiotensin-converting enzyme inhibitors (ACEI), and statins have demonstrated efficacy in reducing adverse cardiovascular events.
Early invasive strategies, including percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG), have been shown to improve outcomes in high-risk patients. The selection between PCI and CABG should be individualized based on patient characteristics and coronary anatomy.
Secondary prevention measures, including lifestyle modifications and cardiac rehabilitation, are essential components of ACS management. These measures can reduce the risk of recurrent events and improve quality of life.
In conclusion, ACS management requires a comprehensive approach involving risk stratification, pharmacologic therapy, invasive strategies, and secondary prevention measures. Ongoing research and technological advancements will continue to refine these strategies, with the ultimate goal of improving patient outcomes.
1.
Discovery reveals protein involved in Parkinson's disease also drives skin cancer
2.
The prognosis of the Slovakian PM; Kate Middleton's treatment; and drug test cheating.
3.
We Don't Always Know What's 'Best' for Our Patients
4.
New tumor therapy approach reduces costs and side effects while increasing accessibility
5.
Dual-action mRNA vaccine takes aim at aggressive skin cancer
1.
The Evolving Arsenal: A 2025 Review of Antibody-Drug Conjugates and the Future of Precision Oncology
2.
Case Study: Combining Targeted Therapy with Immunotherapy for Metastatic Melanoma
3.
Anion Gap: The Simple Calculation That Reveals Much About Your Health
4.
Contemporary Methods in Hematology Across Clinical Settings
5.
Unlocking the Potential of Cytarabine: A New Era of Cancer Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
5.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation